Nurix Therapeutics

We were honored to sponsor the The Leukemia & Lymphoma Society's Light The Night event in San Francisco, joining together to support those impacted by blood cancers.     Our mission to develop innovative targeted protein modulation therapeutics to potentially improve the outcomes of those with cancer and other challenging diseases aligns closely with the purpose of this inspiring event—bringing hope, advancing research, and standing with patients and their families.     We are grateful for our team members who came out to light the night and illuminate the path toward a brighter future for all affected by cancer.     #LightTheNight

Nurix’s President and CEO, Arthur T. Sands, M.D., Ph.D., will discuss the latest company updates in a fireside chat at the the Stephens Biotechnology Virtual Fireside Chats on Thursday, November 14, 2024, at 2:30 p.m. ET. Be sure to tune in if you’re attending the conference.

Nurix’s Chief Scientific Officer, Gwenn Hansen, Ph.D., will discuss how Nurix is deploying its innovative targeted protein modulation platform to develop novel therapeutics in a presentation at the SMART Symposium on Wednesday, November 13, 2024, at 2:00 p.m. CST in Shenzhen, China. Learn more here: https://bit.ly/40wMGcq

Nurix’s Chief Financial Officer, Hans van Houte, and Chief Business Officer, Jason Kantor, Ph.D., will discuss the latest company updates in a fireside chat at the UBS Healthcare Conference on Tuesday, November 12, 2024, at 5:00 p.m. PT. Listen to the live or archived discussion here: https://lnkd.in/g-Bm2cR8

Nurix’s President and Chief Executive Officer, Arthur T. Sands, M.D., Ph.D., will participate in a panel discussion at the Truist BioPharma Symposium on Thursday, November 7, 2024, at 10:30 a.m. ET. Be sure to tune in if you’re attending the conference.

More than 234,000 people in the US will be diagnosed with lung cancer this year. At Nurix, we’re using our targeted protein modulation platform to potentially improve outcomes for those facing a diagnosis of cancer, including lung cancer. Learn more about our work here: https://bit.ly/3L7kMKK #LungCancerAwareness 

Nurix’s Chief Business Officer, Jason Kantor, Ph.D., will share his experience in establishing major strategic partnerships during two panel sessions on Wednesday, October 30th at the 7th Annual TPD & Induced Proximity Summit. Learn more about the presentation and summit details here: https://bit.ly/47wOe7L

Nurix’s Chief Medical Officer, Paula OConnor , M.D., will discuss clinical findings from Nurix’s novel first-in-class BTK degrader, NX-5948, for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) at the 7th Annual TPD & Induced Proximity Summit on Wednesday, October 30th, at 9:00 a.m. ET.   Learn more about the presentation and summit details here: https://bit.ly/47wOe7L

Nurix’s Associate Director of Cell Biology & Project Lead, Ya-Wen Lu, Ph.D., will discuss Nurix’s development of novel BRAF degraders to treat solid tumors in a presentation at the 7th Annual TPD & Induced Proximity Summit on Tuesday, October 29th, at 11:30 a.m. ET. Learn more about the presentation and summit details here: https://bit.ly/47wOe7L

Nurix’s CEO, Arthur T. Sands, M.D., Ph.D., will join fellow CEOs from other leading targeted protein degradation companies to discuss the current landscape in this exciting field and share strategic advice on advancing multiple #TPD programs through discovery and development to enable clinical success. “The CEO Think Tank” panel will take place on Tuesday, October 29th at 9:30 a.m. ET during the 7th Annual TPD & Induced Proximity Summit. Learn more here: https://bit.ly/47wOe7L